title: Targeting of Sp1 transcription factor: a novel therapeutic approach for keloids, an in vitro analysis.
abstract: Keloid scars are fibroproliferative disorders characterized by the accumulation of extracellular matrix (ECM) components resulting in a fibrotic condition. Several ECM promoters are regulated by Sp1. Thus, our aim was to investigate the role of Sp1 in keloid pathogenesis and investigate the antiproliferative and antifibrotic effects of Wp631 and mitoxantrone, potent inhibitors of Sp1-activated transcription. An elevated level of Sp1 was observed in tissue extracts obtained from keloid tissue. Serum stimulation elevated Sp1 levels in keloid fibroblasts (KF). Under coculture conditions Sp1 seemed to be downregulated. Wp631 and mitoxanthrone in serum growth factors resulted in a reduced expression of ECM components in KF. Both Wp631 and mitoxanthrone were also able to inhibit the proliferation of normal and keloid keratinocytes and fibroblasts significantly. As Wp631 seems to be potent in downregulating the ECM components in KF and also inhibiting the proliferation of these cells it could be explored as a possible therapeutic agent in the treatment of keloids.
authors.affiliation: Department of Pharmacy, National University of Singapore, Singapore.
authors.forename: A
authors.initials: A
authors.lastname: Mukhopadhyay
authors.forename: A
authors.initials: A
authors.lastname: Khoo
authors.forename: H H
authors.initials: HH
authors.lastname: Cheong
authors.forename: S Y
authors.initials: SY
authors.lastname: Chan
authors.forename: O
authors.initials: O
authors.lastname: Aalami
authors.forename: I J
authors.initials: IJ
authors.lastname: Lim
authors.forename: T T
authors.initials: TT
authors.lastname: Phan
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016022:Case-Control Studies; D002467:Cell Nucleus / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D018920:Coculture Techniques; D003094:Collagen / Q000378:metabolism; D015536:Down-Regulation; D005109:Extracellular Matrix / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D007627:Keloid / Q000188:drug therapy / Q000378:metabolism*; D015603:Keratinocytes / Q000187:drug effects* / Q000378:metabolism; D008942:Mitoxantrone / Q000494:pharmacology / Q000627:therapeutic use*; D016329:Sp1 Transcription Factor / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013778:Tetrazolium Salts; D013844:Thiazoles; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; D005353:Fibronectins; D016329:Sp1 Transcription Factor; D013778:Tetrazolium Salts; D013844:Thiazoles; D003094:Collagen; D008942:Mitoxantrone; C022616:thiazolyl blue